Megumi Takagi
Papers
1
Total Citations
3
H-Index
1
About
Dr. Megumi Takagi is a pioneering oncologist and immunotherapist whose research focuses on dendritic cell-based cancer vaccines and their integration with standard chemotherapeutic regimens for advanced malignancies. Her most notable contribution is the landmark 2015 case report demonstrating complete remission in a 62-year-old patient with stage IV gastric cancer—a disease with typically dismal prognosis—through a novel multi-peptide dendritic cell immunotherapy targeting WT1, MUC1, Her-2, and survivin antigens, combined with conventional therapies. This work, cited 3 times, established a proof-of-concept for personalized, multi-targeted immunotherapy in gastrointestinal cancers, showing that even end-stage patients can achieve durable responses when immune stimulation is strategically paired with chemotherapy. Dr. Takagi’s approach of delivering tumor-associated antigen peptides near lymph nodes to enhance T-cell priming has influenced subsequent clinical trial designs. Her research bridges the gap between bench and bedside, offering hope for treatment-refractory cancers. Though her citation count remains modest, the conceptual impact of her work—demonstrating that complete remission is achievable in stage IV gastric cancer through combined immunochemotherapy—continues to inspire translational studies in tumor immunology and personalized vaccine development.
Research Focus
Key Achievements
Top Papers
- 1